or Try an Advanced Search...

    Technical Analysis for TYRA - Tyra Biosciences, Inc.

    Grade Last Price % Change Price Change
    F 15.87 -2.10% -0.34
    TYRA closed down 2.1 percent on Wednesday, November 20, 2024, on 69 percent of normal volume.
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Down
    Historical TYRA trend table...
    Date Alert Name Type % Chg
    1,2,3 Retracement Bearish Bearish Swing Setup 0.00%
    Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
    MACD Bullish Signal Line Cross Bullish 0.00%
    Spinning Top Other 0.00%
    Wide Bands Range Expansion 0.00%
    Wide Bands Range Expansion -2.10%
    Oversold Stochastic Weakness -2.10%
    NR7 Range Contraction 2.59%
    Narrow Range Bar Range Contraction 2.59%
    Inside Day Range Contraction 2.59%
    Older End-of-Day Signals for TYRA ...

       Recent Intraday Alerts

    Alert Time
    60 Minute Opening Range Breakdown about 18 hours ago
    Down 3% about 18 hours ago
    60 Minute Opening Range Breakout about 20 hours ago
    Up 1% about 20 hours ago
    10 DMA Support about 21 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    TYRA Chart by TradingView
    Basic chart:

    Profile

    Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2-related cancers, FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. Tyra Biosciences, Inc. was incorporated in 2018 and is headquartered in Carlsbad, California.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Cancer Biology Tumor Cell Biology Tyrosine Kinase Receptors Bladder Cancer Preclinical Stage Biopharmaceutical Clusters Of Differentiation Fibroblast Growth Factor Fibroblast Growth Factor Receptor

    Is TYRA a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 13 Tyra Biosciences to Present at Upcoming Investor Conferences
    Nov 8 Tyra Biosciences GAAP EPS of -$0.41 beats by $0.06
    Nov 7 Tyra Biosciences Reports Third Quarter 2024 Financial Results and Highlights
    Nov 3 Chief Financial Officer of Tyra Biosciences Alan Fuhrman Buys 284% More Shares
    Oct 28 Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Pediatric Achondroplasia (BEACH301)
    Oct 25 Tyra stock plunges 17% amid TYRA-300 study data release
    Oct 24 Tyra Biosciences Reports Interim Clinical Proof-of-Concept Data for TYRA-300, an Investigational Oral FGFR3-Selective Inhibitor, in Phase 1/2 SURF301 Study in Patients with Metastatic Urothelial Cancer (mUC)
    Oct 23 Tyra Biosciences to Host Conference Call on Interim Clinical Data of TYRA-300 from SURF301 Phase 1/2 Study on October 25, 2024, at 8am ET
    Oct 21 Tyra Biosciences: Upcoming FGFR3 Inhibitor Data Is A Major Inflection Point
    Oct 20 Here's Why We're Not Too Worried About Tyra Biosciences' (NASDAQ:TYRA) Cash Burn Situation
    See more TYRA news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 29.6
    52 Week Low 10.6004
    Average Volume 371,160
    200-Day Moving Average 19.23
    50-Day Moving Average 21.00
    20-Day Moving Average 17.36
    10-Day Moving Average 16.05
    Average True Range 1.39
    RSI (14) 36.31
    ADX 30.51
    +DI 16.49
    -DI 27.72
    Chandelier Exit (Long, 3 ATRs) 25.42
    Chandelier Exit (Short, 3 ATRs) 19.22
    Upper Bollinger Bands 23.33
    Lower Bollinger Band 11.39
    Percent B (%b) 0.38
    BandWidth 68.80
    MACD Line -1.73
    MACD Signal Line -1.75
    MACD Histogram 0.0197
    Fundamentals Value
    Market Cap 830.71 Million
    Num Shares 52.3 Million
    EPS -1.39
    Price-to-Earnings (P/E) Ratio -11.42
    Price-to-Sales 0.00
    Price-to-Book 4.30
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 17.31
    Resistance 3 (R3) 17.36 16.94 17.07
    Resistance 2 (R2) 16.94 16.57 16.91 16.99
    Resistance 1 (R1) 16.40 16.34 16.19 16.35 16.91
    Pivot Point 15.98 15.98 15.87 15.95 15.98
    Support 1 (S1) 15.44 15.61 15.23 15.39 14.83
    Support 2 (S2) 15.02 15.38 14.99 14.75
    Support 3 (S3) 14.48 15.02 14.67
    Support 4 (S4) 14.43